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The human immune system is capable of recognizing and degrading chitin, an important cell wall component of pathogenic
fungi. In the context of host-immune responses to fungal infections, herein we review the particular contributions and interplay
of fungus and chitin recognition, and chitin-degrading enzymes, known as chitinases. The mechanisms of host chitinase responses
may have implications for diagnostic assays as well as novel therapeutic approaches for patients that are at risk of contracting fatal
fungal infections.
1.Introduction
Recipientsofsolidorgansandhematopoieticcelltransplants,
AIDS patients, and burn victims are usually immunosup-
pressed for extended periods of time. Their prolonged
immunosuppressive state is associated with a high risk of
contracting invasive fungal infections (IFIs) [1, 2]. Most IFIs
advancerapidlyandareoftennotdiagnosedearlyenoughfor
antifungal drugs to function with full eﬃcacy; therefore, the
majority of these infections lead to death [1].
In contrast to immunosuppressed patients, immuno-
competent individuals are protected from fungal infections
by their functional innate immune system, which readily
recognizes and eliminates fungal invaders. Recognition of
fungal cellular features by the immune system appears to
be a key component of the human antifungal defense [3].
For example, β-glucan on the fungal cell wall is recog-
nized as a pathogen-associated molecular pattern (PAMP)
by dectin-1 and activates pro- and anti-inﬂammatory
cytokines in a myeloid-diﬀerentiation-primary-response-
gene-88-(MYD88-) dependent signaling pathway [3–6]. An
important component of the fungal cell wall that has not
been fully explored as a PAMP is chitin, a polymer of N-
acetylglucosamine [3, 7]. Chitin is one of the most abundant
biopolymers, probably almost as abundant as cellulose [8,
9] and is found on fungal cell walls and exoskeletons of
numerous organisms including parasitic worms (helminths)
and arthropods. Although humans do not biosynthesize
chitin, they do express chitin degrading enzymes, known as
chitinases [10–12]. There are two known human chitinases
that have chitinolytic activity, chitotriosidase (CHIT-1) and
acidic mammalian chitinase (AMCase), as well as multiple
noncatalytically active chitinases called chi-lectins [11–14].
The functions of CHIT-1 and AMCase are unknown,
but they are thought to aid in the defense of chitin-
containing pathogens. For instance, in guinea pigs, serum
chitotriosidase levels increase in response to systemic fungal
infection [15]. That chitinase levels can vary in response
to fungal infections suggests the possibility of using host
chitinase responses as a diagnostic. However, several other
stimuli can also upregulate chitinase activity [16–19]a n d
counterproductively, several polymorphisms in the CHIT-1
and AMCase genes are known to decrease chitinase activity
[20–24]. Thus, there are several challenges to be overcome
if chitinase responses were to be used in the diagnosis of
fungal infections. More recently, recombinant CHIT-1 was
shown to have antifungal properties both in vitro and in
vivo, suggesting the possibility of a gene therapy approach
[25]. This paper will explore chitinase responses to fungal
infections,currentknowledgeaboutthemechanismofchitin
recognition by host-immune cells, and regulation of host-
chitinase induction.2 International Journal of Microbiology
2.InvasiveFungalInfections(IFIs)
Fungal infections have become a major disease concern over
the last three decades, in particular for recipients of solid
organs and hematopoietic stem cells, AIDS patients, and
burn victims, all of whom are usually immunosuppressed
for extended periods of time [26–28]. Their prolonged
immunosuppressed status leads to an increased risk of
contracting opportunistic IFIs. IFIs are also on the rise
in intensive care settings, likely due to a growing use of
procedures with invasive medical devices and long-term use
of antibiotics [29]. In all cases, the most common etiological
agents are Candida albicans and Aspergillus fumigatus [27,
29].
Humans are exposed to hundreds of fungal spores each
day, usually without a negative eﬀect on their health. In
the lungs of patients that lack suﬃcient pulmonary immune
defenses, A. fumigatus fungal spores are able to swell,
germinate, and branch into fungal hyphae. The infection
can then disseminate to other organs through the blood-
stream [26, 30]. Healthy individuals are able to eliminate
fungal spores by mucociliary clearance, macrophages, and
other primarily pulmonary defense mechanisms [26]. C.
albicans, on the other hand, is a commensal organism
residing in the gastrointestinal tract and oral, and vaginal
mucosa of most healthy individuals, where it typically
does not produce harmful side eﬀects. However, Candida
overgrowth can become symptomatic causing mucosal
membrane infections, the most common being thrush
and vaginal candidiasis [31–33]. Severe systemic Candida
infections (Candidemia) and dissemination to internal
organs can occur in immunocompromised patients [31–
33].
Current methods for detecting IFIs are based on clinical
signs and microbial examination. For example, pulmonary
fungal infections are typically examined via CT scan, fol-
lowed up with bronchoalveolar lavage (BAL) and biopsy
[27, 30]. Systemic yeast infections such as candidiasis
can be diagnosed by the blood culture [33]. However,
current diagnostic methods usually do not detect fungal
infections at early stages, and therefore, antifungal drug
treatment is oftentimes ineﬃcient or delayed. There are
some serological tests that may be routinely performed
assisting in the diagnosis of fungal infections via detec-
tion of fungal antigens in suspected patients [30]. For
example, the galactomannan assay is sometimes used for
the detection of Aspergillus in serum and BAL ﬂuid. This
assay works by detecting galactomannan released from
the fungal pathogen by enzyme-linked immunosorbent
assays [34, 35]. Elevated levels of galactomannan have
been detected at early stages of fungal infections, how-
ever, the sensitivity and speciﬁcity of this assay has been
criticized [36]. Moreover, the galactomannan assay is not
useful for other fungal pathogens, including Candida [30,
37]. β-1,3-glucan serological detection assays are more
widely used today because they can detect a wide range
of fungi, including Aspergillus and Candida, but they do
not detect zygo- or mucormycosis or cryptococcal disease
[38]. The β-glucan assay works by detecting β-1,3-glucan,
a major component of the fungal cell wall, circulating
in the patient bloodstream [39, 40]. The assay has had
great promise for fungal detection, especially when used to
conﬁrm galactomannan positive results, however, problems
with false-positive (and false-negative) results have been
reported [41, 42]. Despite the availability of such diagnostic
tests, Garcia-Vidal et al. reported an increase in IFIs and
lack of detection at an early stage, within 40 days after
hematopoietic cell transplant in infected patients, demon-
stratingtheineﬀectivenessofpresentdaydiagnosticmethods
[27].
3.FungalCellWallComponents andPattern
RecognitionReceptors
Generally, the innate immune system’s response to PAMPs,
which include glycosides, glycolipids, and carbohydrates,
among others, involves pattern recognition receptors (PRRs)
that are expressed by phagocytes. Pattern recognition then
leads to a cascade of cellular signaling that activates phago-
cytes for defense [3, 26]. The recognition of fungal cellular
features, in particular fungal cell wall components, by the
immune system of the host is an important element for
mounting an antifungal defense response [3, 5, 26, 43]. The
fungal cell wall is composed of various mannoproteins, β-
glucansaswellasathin,rigidlayerofchitin(Figure 1).Many
PRRsinteractwithfungalcellwallcomponents.Forexample,
mannoproteins with O-linked protein-carbohydrate conju-
gations are recognized by toll-like receptor (TLR)-4 [3,
44, 45], while mannoproteins that are N-linked can be
recognized by dectin-2, mannose, and Fcγ receptors [3,
45–47]( Figure 2). The galectin-3 receptor recognizes β-
mannosides [44, 48–50]. β-glucan is recognized as a PAMP
by dectin-1 [4, 6] and when coated by phospholipomannan
it is also recognized by both TLR-6 and TLR-2 [51–54].
Complement-coated β-glucan is recognized by complement
receptor-3[55,56].Dectin-1recognitionofβ-glucansresults
in an MYD88-dependent pathway activation [3, 5, 44, 55,
57]. And ﬁnally, fungal CpG DNA is recognized by the
intracellular receptor TLR-9 [58]( Figure 2). Recognition
of fungal cell wall components by these PRRs generally
leads to the nuclear factor kappa-lightchain enhancer of
activated B cells (NF-κB) signaling; this results in the
activation of proinﬂammatory cytokines, such as tumor
necrosis factor (TNF)-α, or anti-inﬂammatory cytokines,
such as interleukin (IL)-10 (Figure 2). Whether chitin in the
fungal cell wall is recognized as a PAMP, and if a speciﬁc
chitin receptor exists as a PRR, remains unknown; yet it is
a very likely possibility [3, 7].
4.Chitinasan ImmuneModulator
Intranasal or intraperitoneal chitin administration to mice
caused an immunological preactivation eﬀect, called prim-
ing, in alveolar macrophages and natural killer (NK) cells
[65].Shibataetal.examinedtheeﬀectsofchitinparticlesizes
on cellular responses, in particular macrophage activation
and priming. Balb/c mouse splenocytes that were coculturedInternational Journal of Microbiology 3
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Figure 1: Fungal cell wall components. The fungal cell wall contains a cell membrane with various membrane proteins, a protective layer
of chitin (yellow) as well as glucans (mostly beta), and mannoproteins on its surface. Diﬀerent fungal cell walls contain diﬀerent glucans.
For example, the cell wall of A. fumigatus contains β-1,3- and β-1,4-glucan, and α-1,3-glucan [30], while C. albicans contains β-1,3- and
β-1,6-glucan [44].
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Figure 2: Fungal cell wall pathogen-associated molecular patterns (PAMPs) and their host-pattern recognition receptors (PRRs). Various
fungal cell wall components are recognized by speciﬁc PRRs. Some PAMPs are recognized by multiple PRRs; for example, N-linked mannan
is recognized by mannan receptor (MR), dectin-2, and FcγR[ 46, 47]. Phospholipomannan-(PLM-) coated β-glucans are recognized by both
TLR-6 and TLR-2 [53, 54]. Other receptors may involve the signaling pathway of another PRR. For example, galectin-3, which recognizes
β-mannosides, signals through TLR-2 (represented by a curved arrow) [47, 49] dectin-1, when activated by β-glucans can signal to activate
the nuclear factor kappa-lightchain enhancer of activated B cells (NF-κB) on its own or with the help of TLR-2 [4, 45]. Fc gamma receptor
(FcγR) may signal through dectin-2 when activated by N-linked mannan [3, 45, 47, 55]. Recognition of these fungal cell wall components
mediates fungal recognition and defense by the host. Recognition by host PRRs usually involves signaling through NF-κB and activation
of proinﬂammatory cytokines, such as TNF-α, or in some instances, and anti-inﬂammatory cytokines such as interleukin (IL)-10 [45].
The possibility of an alternative chitin receptor exists, activation of which leads to the recruitment of IL-4 producing cells [45, 59]. However,
chitinhasbeenshowntofunctionasaThelper(Th)1immunemodulator,whichstandsincontrastanIL-4associatedTh2response[60–64].
with chitin particles (50–100μm), produced, and secreted
IL-12, TNF-α,a n dI F N - γ [60]. However, intravenous injec-
tion of phagocytosable small chitin particles (1–10μm) into
C57 mice resulted in a macrophage priming that was dose
dependent[61].WhenutilizingaSCIDmousemodelinstead
of the C57 mice, the same chitin-macrophage priming eﬀect
wasalsofound.BecauseSCIDmicelackmatureBandTcells,
theauthorsconcludedthatneitherTnorBlymphocyteswere
required for chitin-induced macrophage priming. An NK
cell depletion experiment with anti-NK1.1 antibodies (anti-
CD161c) then demonstrated a requirement for NK cells and
NK-secreted IFN-γ in chitin-induced macrophage priming
[61]. However, as we describe below, chitin particles can also
be used to activate macrophages and monocytes directly in
cell-culture experiments.
It should be noted that chitin can also serve as an
immunoadjuvant [65]. Orally administered chitin sup-
pressed the production of T helper (Th)2 cytokines and
immunoglobulin (Ig)E in a ragweed allergy mouse model
and induced IFN-γ instead [62]. In addition, when used as
an adjuvant, chitin produced Th1 responses comparable to
other adjuvants, including heat-killed Mycobacterium bovis,
Freud’scompleteadjuvant,andtheBacillusCalmette-Gu´ erin
vaccine [63]. Chitin produced eﬀects similar to those of4 International Journal of Microbiology
a Th1-promoting adjuvant in mouse models of ovalbumin-
induced asthma and allergic hypersensitivities induced by
the house dust mite Dermatophagoides pteronyssinus and by
the fungal pathogen A. fumigatus [64, 66]. Chitin admin-
istration signiﬁcantly reduced allergen-induced serum IgE
levels and lung inﬂammation. Th1 cytokines IL-12, IFN-γ,
and TNF-α were elevated, while IL-4 levels were decreased in
mice-administered chitin as compared to controls [64, 66].
These and other studies strongly suggest that the immune
system possesses a chitin recognition mechanism.
5.Mammalian Chitinases
Another immune response that may correlate with chitin
recognition is the production of chitin-degrading enzymes,
known as chitinases, by humans and other mammals.
Chitinases belong to the glycosyl hydrolase 18 family, which
is comprised of various proteins found in a wide range
of organisms, including plants, bacteria, fungi, insects,
protozoa, and mammals [13]. Six proteins with homology to
chitinases have been identiﬁed in mammals. These include
CHIT-1 and AMCase, which are the only two enzymatically
active human chitinases able to hydrolyze chitin [11, 12,
14]. The other four of these highly homologous members
of the chitinase family contain amino acid substitutions
at their active sites, rendering these proteins noncatalytic.
These noncatalytic chitinases are referred to as chi-lectins or
chitinase-like proteins, and include chitinase-3-like protein
1 (CHI3L1, also known as YKL-40, Hcgp39, or GP39),
stabilin-interacting chitinase-like protein (SI-CLP), YKL-39
(chitinase 3-like protein 2), and oviductin [13].
CHIT-1 is highly expressed by activated macrophages
a n di su s e da sam a r k e rf o rm a c r o p h a g es t i m u l a t i o n ,
suggesting a possible role in innate immunity [67, 68]. It
was ﬁrst discovered in the plasma of patients with Gaucher’s
disease; a disease characterized by the accumulation of lipid-
laden macrophages [68–70]. The use of a chitinase detection
assay, which measures the presence of chitinase activity via
cleavage of the ﬂuorogenic substrate 4-methylumbelliferyl
chitotriosidase,showedthatCHIT-1levelswereelevatedsev-
eral hundred-fold in the plasma of patients with Gaucher’s
disease. Therefore, CHIT-1 is now being used as a biomarker
for the diagnosis of Gaucher’s disease [68, 69, 71]. These
ﬁndings drew attention to the cloning and further char-
acterization of CHIT-1 [72, 73] and the discovery of the
other enzymatically active human chitinase, AMCase. The
sequence of AMCase is highly homologous to that of CHIT-
1; however, AMCase is unique in that it functions strongest
in acidic pH environments. Consistently, it was ﬁrst found
highly expressed in the stomach, intestinal tissue, and more
recently is being studied as a biomarker for asthma and other
hypersensitivities [11, 12, 27, 74].
Evolutionarily, chitinase production plays an important
role in the life cycles of chitin-containing organisms such
as fungi, insects and crustaceans, in which it is involved in
either cell wall remodeling or molting. However, because
mammals do not produce chitin, the physiological function
of these chitinases and chi-lectins remains unclear, but
various studies suggest that their function may lie in the
digestion of chitin-containing foods and defense against
chitin-containing pathogens and parasites [11, 13, 75].
6.ChitinasesinExperimental
Antifungal Therapy
Chitinases have also been investigated for their potential use
in antifungal therapy. Low concentrations of recombinant
human CHIT-1 degraded the cell walls of Cryptococcus
neoformans and visibly inhibited its growth in vitro [67].
Morphological changes, such as atypical blebs, hyphal tip
bursting, and restrictions of hyphal growth, were also
observed for Mucor rouxii and C. albicans in the presence
of recombinant CHIT-1 [67]. In addition, recombinant
human CHIT-1 induced a dose-dependent improvement
in the survival of mice with C. albicans and A. fumigatus
infections [67]. Recently, it was shown that the culture
medium conditioned by Chinese hamster ovary cells that
had been retrovirally transfected with the human CHIT-1
gene had antifungal activity [25]. These modiﬁed Chinese
hamster ovary cells were then encapsulated in alginate
microspheresandinjectedsubcutaneouslyintoBALB/cmice,
where they continuously secreted active CHIT-1, and after
infection with C. neoformans, mice harboring these cells
had signiﬁcantly lower fungal burden [25]. Therefore, the
authors suggested that a continuous supply of active CHIT-1
should be explored in future gene therapies to prevent fungal
infections.
7.Mammalian ChitinaseResponses to
Inﬂammation andFungalInfections
Multiple stimuli, such as exposure to prolactin, interferon
gamma (IFN-γ), lipopolysaccharides (LPS), and TNF-α
can upregulate chitinase activity in human monocytes and
macrophages, indicating a possible role for chitinase activity
in inﬂammation [16–19]. Chitinase activity was reported to
be upregulated as a result of various diseases, including can-
didiasis [76], Wuchereria bancrofti infections (ﬁlariasis) [21],
and helminth infections [77, 78]. AMCase activity is highly
upregulated in individuals suﬀering from asthma, chronic
rhinosinusitis, or allergic bronchopulmonary aspergillosis
[77, 78]. In addition, chitinase activity has been linked to
fungal infections. In 1996, Overdijk et al. showed that, in
guinea pigs, chitinase activity was induced after systemic
infection with A. fumigatus [15, 79]. Furthermore, mice with
pulmonary C. neoformans exposure had increased AMCase
chitinase activities in the airways [80]. Intraperitoneal
injections of zymosan, a yeast-cell wall-derived product that
contains beta-glucans and small quantities of chitin, was
shown to increase serum chitinase activity of rats [81].
Although chitinase activity does not appear to be speciﬁc
for fungal infections, as it is also upregulated in other
diseases, there appears to be a correlation between chitinase
activity and inﬂammation as well as with disease induced
by chitin-containing pathogens. These ﬁndings suggest
that mammalian chitinase responses to fungal infectionsInternational Journal of Microbiology 5
and other parasitic infections may be triggered by the host
response to a chitin-containing pathogen.
8. ChitinaseInduction andRegulation
Little is known about how host chitinase activity is induced,
but there is some indication that chitinase production and
chitin recognition could be linked. Gorzelanny et al. used
MALDI-TOF mass spectrometry to analyze the degradation
of chitin by chitotriosidase and followed the stimulation of
human monocyte/macrophage with a chitin hexamer [82].
These studies revealed that chitinases degrade chitin into
smaller chitin-oligomers that in turn enhance the stimula-
tion of macrophages, leading to more chitinase production
[82].However,thefeedbackmechanismofchitinrecognition
and chitinase secretion suggested by this study is still unclear
andthesignalingpathwaysinvolvedarenotfullyunderstood.
Other chitin stimulation experiments revealed some
aspects of the mechanism involved in the recognition
of chitin and chitin-containing parasites by immune
cells. Jumonji domain containing-3 (Jmjd3), a histone 3
Lys27 (H3K27) demethylase, along with Irf4 transcription
factor, was determined to be essential for macrophage
colony-stimulating factor (M-CSF)-bone-marrow-derived
M2 macrophage polarization in response to Nippostrongylus
brasiliensis helminth infection and chitin inoculation [59].
Another group found that mice exposed to N. brasiliensis
helminth infection showed tissue invasion by macrophages
and IL-4- and IL-13-producing immune cells as well as
eosinophil recruitment [83]. Furthermore, transgenic mice
that overexpressed AMCase in the lung, and were also
exposed to N. brasiliensis, showed diminished inﬁltration
of immune cells. The diminished inﬁltration of cells was
likely due to N. brasiliensis chitin degradation and removal
[83]. The same eﬀect was observed when chitin alone
was injected, and the eﬀect was sustained, even in TLR-4-
deﬁcient animals [83].The lattereﬀectis interesting, because
TLR-4, which recognizes LPS and leads to activation of the
innate immune system, was previously considered a possible
chitin PRR candidate [44]. The observed recruitment of IL-
4 producing immune cells by chitin stands in stark contrast
to the previously observed Th1 immune response induced
by chitin when used as an adjuvant (see above). IL-4 is
a typical Th2 response-inducing cytokine. It is possible
though, that the IL-4 production by recruited immune cells
is a secondary eﬀect that requires other chemokines or other
chemoattractants to be produced by primary chitin-sensing
cells.
In contrast to TLR-4, TLR-2 and the IL17A receptor (IL-
17AR)mayatleastbepartiallyinvolvedinchitinrecognition.
Da Silva et al. reported that mouse macrophages stimulated
withchitin particleshadincreasedlevelsofIL-17proteinand
IL-17AR mRNA, and the increase in IL-17 was mediated via
the TLR-2 pathway. In vivo investigations demonstrated that
chitin induces acute pulmonary inﬂammation in wild-type
mice, but not in TLR-2 knockout mice [84]. Therefore, it
is possible that TLR-2 and IL-17AR are somehow involved
in the recognition of chitin. TLR-2 is known to recognize
bacterial particles, LPS, and more interestingly, zymosan,
which contains chitin (see above) [44].
Portions of the downstream signaling pathway that
leads to chitinase expression have been analyzed. CHIT-1
mRNA expression in monocytes increases upon treatment
with phorbol 12-myristate 13-acetate (PMA), which induces
diﬀerentiation of monocytes into activated macrophages
[85]. In addition, CHIT-1 gene activation is accompanied
by the binding of phosphorylated CCAAT-enhancer-binding
protein (C/EBP)β and the transcription factor PU.1 to the
promoter region of CHIT-1 (Figure 3)[ 85]. The upstream
molecular signaling pathway leading to CHIT-1 gene acti-
vation and chitinase induction has not been determined;
however, roles for some key proteins involved in chitinase
r e g u l a t i o nh a v eb e e nn o t e d[ 16–19]. Chitinase gene expres-
sion and activity was induced by human-monocyte-derived
macrophages after prolactin stimulation in both a dose- and
time-dependent manner [17]. Because prolactin has similar
structural properties as some proinﬂammatory cytokines,
alternative stimulations were preformed with IFN-γ,T N F -
α, and LPS, and, as a negative control, with IL-10, which has
anti-inﬂammatoryproperties.Chitinaseactivitywaselevated
in human monocyte-derived macrophages after stimulation
with IFN-γ,T N F - α, and LPS and was signiﬁcantly decreased
after stimulation with IL-10 [16, 19]. These ﬁndings may
indicate the involvement of chitinase activity induction
during inﬂammatory conditions. Prolactin stimulation of
human monocyte-derived macrophages was also performed
in the presence or absence of speciﬁc kinase inhibitors
[18]. The phosphatidylinositol 3-kinase (PI3-K) inhibitors
wortmanninandLY-294002reducedchitinaseactivity,asdid
the protein tyrosine kinase inhibitor genistein, the mitogen-
activated kinase (MAPK) p38 inhibitor SB203580, and the
MAPK p44/42 inhibitor U0126. No eﬀect was observed on
prolactin-mediated chitinase induction when the contro-
versial protein kinase C inhibitor rottlerin was used, nor
was an eﬀect seen with PP2, a Src inhibitor, or AG490, a
JAK2 inhibitor [18]. Accordingly, CHIT-1 induction can be
mediated via a PI3-K/MAPK pathway (Figure 3).
9. Polymorphisms inChitinaseProteins
The induction of chitinase activity as an immune response
to various stimuli such TNF-α, prolactin, and chitin, and
in response to fungal infections suggests that chitinases
are indeed involved in the host’s immune response to a
pathogenic fungal invader. However, multiple known poly-
morphisms can aﬀect chitinase activity, the most prominent
being a 24-bp duplication in the CHIT-1 gene. The CHIT-1
gene is composed of 12 exons and the protein is secreted as
two isoforms. The major isoform has a molecular mass of
50kDa, undergoes posttranslational modiﬁcations, includ-
ing O-linked glycosylation of the C-terminal region (which
contains the chitin-binding domain) and is alternatively
splicedinto the39kDaminor isoform[20,68].Sometimes, a
24-bp duplication occurs in exon 10 of CHIT-1 that causes a
downstream cryptic 3  splice site that generates mRNA with
an in-frame deletion of 87 nucleotides (29 amino acids).6 International Journal of Microbiology
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in the recognition of most fungal cell wall components (see Figure 2)[ 45]; therefore, its involvement in the expression of chitinase in
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or particles and mediate chitinase activity. Prolactin stimulation of macrophages leads to chitinase expression via a PI-3K, MAPK, and
NF-κBp a t h w a y[ 16–19]. Activation of Jmjd3, leads to demethylation of H3K27 and recruitment of the transcription factor Irf4, which is
associated with M2 macrophage polarization in response to chitin stimulation [59]. Expression of the chitinase encoded by the CHIT-1 gene
is regulated via PU.1 and C/EBPβ. The latter is phosphorylated (p) to induce CHIT-1 expression [85]. NF-κB, nuclear factor kappa-light-
chain-enhancer of activated B cells; IFN-γ: interferon gamma; NK cells: natural killer cells; LPS: lipopolysaccharide; TNF-α: tumor necrosis
factor alpha; PMA: phorbol 12-myristate 13-acetate; IL-17: interleukin-17; IL-17-AR: interleukin-17A receptor; TLR-2: toll-like receptor-2;
PI-3K: phosphatidylinositol 3-kinase; MAPK: Mitogen-activated protein kinase; Jmjd3: Jumonji domain containing-3; H3K27: histone 3
Lys27 demethylase; CHIT-1: chitotriosidase; C/EBPβ: CCAAT-enhancer-binding protein beta.
This mutant protein can bind chitin particles, but cannot
degrade chitin [20, 86]. Macrophages from individuals with
this 24-bp duplication in the CHIT-1 gene produced CHIT-
1 RNA and small amounts of a 47kDa protein, but no
enzymatically active chitotriosidase [20]. Approximately 30–
40% of the human population is heterozygous and 3–6%
is homozygous for this duplication [20, 77, 86]. The use of
chitinase activity as a disease biomarker may therefore be
limited to patients with at least one wild-type CHIT-1 allele.
Theeﬀectofenvironmentalconditionsontheoccurrence
of the most prominent chitinase polymorphism, the 24-
bp duplication, was studied by Malaguarnera et al. DNA
analysis was performed to compare the frequency of the
exon 10 duplication allele in individuals from Mediterranean
countries and sub-Saharan regions. This study found a
higher frequency of individuals homozygous for the 24-
bp duplication in Sicily and Sardinia, 3.73% and 5.45%,
respectively, than in people from Benin and Burkina
Faso (frequency of 0% homozygous for the duplication).
The authors concluded that the presence of the CHIT-1-
inactivating 24-bp duplication in Sicily and Sardinia was due
to the improved, more sanitary environmental conditions
as compared to Benin and Burkina Faso, which still face
widespread parasitic diseases and the presence of multiple
chitin-containing pathogens [77]. The lack of chitotriosi-
dase activity in people with these polymorphisms may be
compensated for by AMCase chitinase activity. However,
there are also various polymorphisms that aﬀect AMCase
activity [22, 23, 87]. Therefore, a thorough immunogenetic
haplotype analysis that involves CHIT-1 and AMCase alleles,
as well as chitin sensing and chitinase regulation path-
ways is needed to investigate the signiﬁcance of human
chitinase responses to fungal infections. It is possible that
the dysregulation of chitin sensing or chitinase induction
pathways could be associated with altered susceptibility for
IFIs.International Journal of Microbiology 7
10. Concluding Remarks andFutureDirections
An eﬃcient method for early diagnosis and treatment of IFIs
is needed [27, 30]. Exploiting host responses to IFIs could
help to better understand fungal recognition by the immune
system, and may reveal potential diagnostic markers of IFIs.
A substantial increase in chitinase activity, in conjunction
with other IFIs clinical signs and symptoms, or in con-
junction with the β-1,3-glucan assay could be a biomarker
indicative of a beginning fungal infection. Chitinase activity
appearstoplayanimportantroleinvariousdiseases[13,68],
and therefore, a clear understanding of the processes of
chitinase induction and regulation is desirable.
Chitinases can be induced by various stimuli including
prolactin, TNF-α,I F N - γ, and PMA. And recombinant
humanCHIT-1hasdemonstratedantifungalpropertiesboth
in vivo and in vitro [25, 67]. Therefore, it is conceivable that
artiﬁcial induction of chitinase production in patients that
are at risk of fungal infections could increase their resistance
to fungal pathogens. This strategy would be most eﬀective in
patients with genes encoding catalytically active chitinases.
In summary, chitinase-based diagnostic assay or antifungal
therapeutics may be developed in the near future.
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